Mycobacterium Vaccine Compositions for Immune System Modulation
Summary
The USPTO published patent application US20260091098A1 by inventor Bruce S. Gillis covering methods and compositions using killed or inactivated Mycobacterium or antigenic fragments for modulating immune system function. The application was filed September 12, 2025, under Application No. 19327636. This is a published patent application and does not grant any rights or impose obligations on third parties at this time.
What changed
Bruce S. Gillis filed Application US20260091098A1 with the USPTO covering compositions comprising killed or inactivated Mycobacterium or antigenic fragments, along with methods for assessing alterations in immune system functioning following administration. The application includes CPC classifications A61K 39/04 (Mycobacterium), A61P 37/04 (immunostimulants), and related subclasses under A61K 2039.
Patent applications are published notices that do not create immediate obligations or compliance requirements. Third parties are not required to act but should monitor the application status, as grant of this patent could affect freedom to operate in the immune modulation vaccine space. No enforcement deadlines, penalties, or specific compliance obligations arise from publication of this application.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE SYSTEM FUNCTION
Application US20260091098A1 Kind: A1 Apr 02, 2026
Inventors
Bruce S. GILLIS
Abstract
The invention provides methods and compositions for modulating the immune system of an individual. The methods provided herein entail administering a composition comprising a killed or inactivated Mycobacterium or antigenic fragments derived therefrom. Also provided herein are methods for assessing alteration of immune system functioning following administration of a composition comprising aa killed or inactivated Mycobacterium or antigenic fragments derived therefrom.
CPC Classifications
A61K 39/04 A61P 37/04 A61K 2039/52 A61K 2039/521 A61K 2039/522 A61K 2039/58
Filing Date
2025-09-12
Application No.
19327636
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.